IRIDEX (NASDAQ:IRIX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note released on Monday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Price Performance

IRIDEX stock opened at $0.80 on Monday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54. IRIDEX has a one year low of $0.78 and a one year high of $3.65. The company has a market cap of $13.31 million, a P/E ratio of -1.19 and a beta of 0.94. The business has a fifty day moving average of $1.49 and a two-hundred day moving average of $1.64.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.